Functional Liver After SBRT

Launched by THE NETHERLANDS CANCER INSTITUTE · Jun 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how radiation treatment affects liver function in patients with liver metastases, which are cancer spots that have spread to the liver. The researchers want to understand how different levels of radiation impact the liver’s ability to work properly. To do this, they use a special imaging test called hepatobiliary scintigraphy (HEBIS), which looks at how well the liver is functioning before and a few months after the radiation treatment known as stereotactic body radiotherapy (SBRT). This information will help doctors deliver safer, more personalized radiation doses that protect as much healthy liver as possible while treating the cancer.

Patients who have liver metastases and are scheduled to receive SBRT with a specific treatment plan (3 sessions of 20 Gy each) may be eligible to join the study. To participate, patients need to be able to give informed consent and meet certain health criteria, such as having good kidney function and no recent liver-related infections or treatments that could affect the results. During the study, participants will undergo the HEBIS scan before their radiation treatment and again about 3 to 4 months afterward. The scan requires lying still for up to an hour but is otherwise non-invasive. This study is currently not yet recruiting and will include about 10 to 15 patients to help improve future liver cancer treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient treated for a liver metastasis with SBRT with treatment prescription of 3 x 20 Gy
• • Able to provide informed consent prior to any study specific procedure
• Exclusion Criteria:
• • WHO \> 2
• • Pregnancy
• • Prior radiation therapy of the liver
• • Lactation, unable to substitute for 24 hours
• • Inability to cooperate with the scan process: inability to lie relatively still and in supine for 30-60 minutes or patient body habitus above scanner dimensions
• Exclusion criteria for HEBIS scan:
• • GFR \< 30 ml/min/1.73m2
• • \< 2 weeks after antiviral eradication therapy for hepatitis C
• • Bilirubine \> 30 µmol/l
• • Relative contra-indications (possibly affecting liver function): opiates, barbiturates, somatostatine, colestyramine, rifampicine, atropine